Literature DB >> 16144802

Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.

Bi-Sen Ding1, Claudia Gottstein, Andrea Grunow, Alice Kuo, Kumkum Ganguly, Steven M Albelda, Douglas B Cines, Vladimir R Muzykantov.   

Abstract

Means to prevent thrombus extension and local recurrence remain suboptimal, in part because of the limited effectiveness of existing thrombolytics. In theory, plasminogen activators could be used for this purpose if they could be anchored to the vascular lumen by targeting stably expressed, noninternalized determinants such as platelet-endothelial-cell adhesion molecule 1 (PECAM-1). We designed a recombinant molecule fusing low-molecular-weight single-chain prourokinase plasminogen activator (lmw-scuPA) with a single-chain variable fragment (scFv) of a PECAM-1 antibody to generate the prodrug scFv/lmw-scuPA. Cleavage by plasmin generated fibrinolytically active 2-chain lmw-uPA. This fusion protein (1) bound specifically to PECAM-1-expressing cells; (2) was rapidly cleared from blood after intravenous injection; (3) accumulated in the lungs of wild-type C57BL6/J, but not PECAM-1 null mice; and (4) lysed pulmonary emboli formed subsequently more effectively than lmw-scuPA, thereby providing support for the concept of thromboprophylaxis using recombinant scFv-fibrinolytic fusion proteins that target endothelium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16144802      PMCID: PMC1895234          DOI: 10.1182/blood-2005-05-2002

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury.

Authors:  Benjamin D Kozower; Melpo Christofidou-Solomidou; Thomas D Sweitzer; Silvia Muro; Donald G Buerk; Charalambos C Solomides; Steven M Albelda; G Alexander Patterson; Vladimir R Muzykantov
Journal:  Nat Biotechnol       Date:  2003-03-24       Impact factor: 54.908

2.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.

Authors:  Juan-Carlos Murciano; Sandra Medinilla; Donald Eslin; Elena Atochina; Douglas B Cines; Vladimir R Muzykantov
Journal:  Nat Biotechnol       Date:  2003-07-06       Impact factor: 54.908

3.  The kringle stabilizes urokinase binding to the urokinase receptor.

Authors:  Khalil Bdeir; Alice Kuo; Bruce S Sachais; Ann H Rux; Yasmina Bdeir; Andrew Mazar; Abd Al-Roof Higazi; Douglas B Cines
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

4.  Medicine. Stroke--tPA and the clinic.

Authors:  John R Marler; Larry B Goldstein
Journal:  Science       Date:  2003-09-19       Impact factor: 47.728

Review 5.  Endothelial endocytic pathways: gates for vascular drug delivery.

Authors:  Silvia Muro; Michael Koval; Vladimir Muzykantov
Journal:  Curr Vasc Pharmacol       Date:  2004-07       Impact factor: 2.719

6.  ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface.

Authors:  Juan-Carlos Murciano; Silvia Muro; Lauren Koniaris; Melpo Christofidou-Solomidou; David W Harshaw; Steven M Albelda; D Neil Granger; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

7.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy.

Authors:  Phil Oh; Yan Li; Jingyi Yu; Eberhard Durr; Karolina M Krasinska; Lucy A Carver; Jacqueline E Testa; Jan E Schnitzer
Journal:  Nature       Date:  2004-06-10       Impact factor: 49.962

8.  A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo.

Authors:  Ken-ichi Ogawara; Marianne G Rots; Robbert J Kok; Henk E Moorlag; Anne-Miek Van Loenen; Dirk K F Meijer; Hidde J Haisma; Grietje Molema
Journal:  Hum Gene Ther       Date:  2004-05       Impact factor: 5.695

9.  Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.

Authors:  C E Hagemeyer; I Tomic; U Weirich; J Graeber; T Nordt; M S Runge; C Bode; K Peter
Journal:  J Thromb Haemost       Date:  2004-05       Impact factor: 5.824

10.  Lung endothelium targeting for pulmonary embolism thrombolysis.

Authors:  Bi-Sen Ding; Ying-Jiang Zhou; Xin-Yuan Chen; Jing Zhang; Pei-Xiang Zhang; Zi-Yong Sun; Xiang-Yang Tan; Jian-Ning Liu
Journal:  Circulation       Date:  2003-11-10       Impact factor: 29.690

View more
  38 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

2.  Endothelial targeting of antibody-decorated polymeric filomicelles.

Authors:  Vladimir V Shuvaev; Marc A Ilies; Eric Simone; Sergei Zaitsev; Younghoon Kim; Shenshen Cai; Abdullah Mahmud; Thomas Dziubla; Silvia Muro; Dennis E Discher; Vladimir R Muzykantov
Journal:  ACS Nano       Date:  2011-08-23       Impact factor: 15.881

Review 3.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

4.  Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium.

Authors:  Vladimir V Shuvaev; Melpo Christofidou-Solomidou; Arnaud Scherpereel; Eric Simone; Evguenia Arguiri; Samira Tliba; Jeremy Pick; Stephen Kennel; Steven M Albelda; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2007-01-08       Impact factor: 9.776

5.  Collaborative Enhancement of Endothelial Targeting of Nanocarriers by Modulating Platelet-Endothelial Cell Adhesion Molecule-1/CD31 Epitope Engagement.

Authors:  Ann-Marie Chacko; Jingyan Han; Colin F Greineder; Blaine J Zern; John L Mikitsh; Madhura Nayak; Divya Menon; Ian H Johnston; Mortimer Poncz; David M Eckmann; Peter F Davies; Vladimir R Muzykantov
Journal:  ACS Nano       Date:  2015-07-13       Impact factor: 15.881

Review 6.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

Review 7.  PECAM-1 isoforms, eNOS and endoglin axis in regulation of angiogenesis.

Authors:  Sunyoung Park; Christine M Sorenson; Nader Sheibani
Journal:  Clin Sci (Lond)       Date:  2015-08       Impact factor: 6.124

Review 8.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

9.  Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Sergei Zaitzev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Khalil Bdeir; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

10.  Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies.

Authors:  Thomas D Dziubla; Vladimir V Shuvaev; Nan Kang Hong; Brian J Hawkins; Muniswamy Madesh; Hajime Takano; Eric Simone; Marian T Nakada; Aron Fisher; Steven M Albelda; Vladimir R Muzykantov
Journal:  Biomaterials       Date:  2007-10-24       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.